texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Stanton C. Goldman, M.D.

General Summary

Stanton C. Goldman, M.D. is the principal investigator for the Children’s Oncology Group at Medical City Dallas, and is currently the chief medical officer for Medical City Children’s Hospital.

Education

Medical degree in 1990 from Boston University School of Medicine, Boston; residency in general pediatrics at Children’s National Medical Center, Washington, D.C., 1990-1993; and fellowship in pediatric hematology/oncology, at Johns Hopkins University Medical Center, Baltimore, 1993-1996.

Medical Practice

Research Interest

An author of more than 30 articles and several book chapters, Dr. Goldman has concentrated his clinical research on tumor lysis syndrome and pediatric mature B non-Hodgkin lymphoma.

Surgery Locations

Other Information

Accolades & Memberships

American Society for Cancer Research, American Academy of Pediatrics, American Society of Clinical Oncology, and American Society of Pediatric Hematology/Oncology. D Magazine recognized Dr. Goldman in July 2002, 2004, 2007, and 2009 as one of Dallas’ best pediatric hematologists/oncologists. He previously served as attending physician in the division of pediatric hematology/oncology at Children’s Hospital of Orange County.

Community Service

Publications

  • Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia:  a Children’s Oncology Group report.

    British Journal of Haematology, 2014

  • Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma:  a Children’s Oncology Group report.

    Leukemia, 2013

  • Translocation associated primitive round cell sarcoma: report of a case and review of the literature.

    Pediatric and Developmental Pathology, 2007

  • A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk of tumor lysis.

    Blood, 2001